---
run_id: halo-evidence-vs-diagnosis-validation-v7-vanilla-03
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: vanilla
run_number: 3
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 301
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
condition_packet_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
output_file: model-outputs/vanilla-03.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 03)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `vanilla`, run 3 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 301, on the frozen condition packet.

## Output

**Recommendation: Run the targeted evidence pass.**

**Why:**
Your current growth is "synthetic." The 18% expansion revenue is a lagging indicator of a sales tactic (discounts for early renewals), not a leading indicator of product-market fit. You are seeing a classic B2B "False Positive": the people paying for the software (the economic buyers) and the people managing the rollout (the ops champions) are happy, but the people actually using the tool (the front-line reviewers) are abandoning it at a rate of 69% after one week.

Scaling now would be an expensive mistake. If you commit the budget to broad expansion and implementation hires based on these skewed metrics, you are essentially subsidizing a churn event that will hit in six to twelve months when the discounts expire and the front-line reviewers' lack of adoption becomes visible to the economic buyers. You must decouple "revenue growth" from "product value" before locking the budget.

**The strongest reason against this:**
It creates a "momentum gap" and risks political friction with Sales and the Board. By pausing discounts and questioning the "upbeat story," you are effectively telling the CEO and Sales leadership that their current victory is an illusion. In a board-packet cycle, admitting that the "market wedge" might be a mirage can be perceived as a lack of confidence or a failure of the product team to execute, potentially jeopardizing your internal standing or the CEO's perceived "win" with the board.

**The observable evidence that would change my mind:**
I would pivot to "Scale Broadly" only if the instrumented reviewer-level data reveals that the 31% retention rate is concentrated entirely within your highest-ACV (Annual Contract Value) accounts and that those specific users are achieving a measurable, auditor-approved reduction in triage time. If the "power users" aren't just gaming the system for enablement meetings, but are actually delivering a quantified business outcome that the customer is willing to pay for *without* a discount, the risk of scaling becomes acceptable.
